Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer

Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer

Abstract HER2-positive (HER2+) breast cancer accounts for 20–25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II...

Full description

Bibliographic Details
Main Authors: Nicola Cosgrove, Alex J. Eustace, Peter O’Donovan, Stephen F. Madden, Bruce Moran, John Crown, Brian Moulton, Patrick G. Morris, Liam Grogan, Oscar Breathnach, Colm Power, Michael Allen, Janice M. Walshe, Arnold D. Hill, Anna Blümel, Darren O’Connor, Sudipto Das, Małgorzata Milewska, Joanna Fay, Elaine Kay, Sinead Toomey, Bryan T. Hennessy, Simon J. Furney
Format: Article
Language:English
Published: Nature Portfolio 2023-09-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-023-00572-9

Internet

https://doi.org/10.1038/s41523-023-00572-9

Similar Items